{"id":296405,"date":"2026-03-12T00:00:00","date_gmt":"2026-03-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0009-2023-biopharma-parkinsons-disease-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-04-22T17:10:57","modified_gmt":"2026-04-22T17:10:57","slug":"cutrcg0009-2026-biopharma-parkinsons-disease-current-treatment-current-treatment-physician-insights-parkinsons","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0009-2026-biopharma-parkinsons-disease-current-treatment-current-treatment-physician-insights-parkinsons\/","title":{"rendered":"Parkinson&#8217;s Disease &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Parkinson&#8217;s Disease (US)"},"content":{"rendered":"<p>The mature Parkinson\u2019s disease treatment market continues to evolve as newly launched pump therapies (i.e., AbbVie\u2019s Vyalev, Supernus\u2019s Onapgo), extended-release levodopa formulations (i.e., Amneal\u2019s Rytary and Crexont), and branded adjunctive therapies (e.g., Amneal\u2019s Ongentys, Kyowa Kirin\u2019s Nourianz, Supernus\u2019s Gocovri) establish niches in the treatment algorithm. These newer brands are designed to optimize and prolong levodopa\u2019s benefits, reduce the severity of levodopa-induced dyskinesia, and reduce the frequency and impact of motor response complications. Understanding neurologists\u2019 prescribing decisions in <abbr title=\"Parkinson's disease\">PD<\/abbr> and the underlying drivers is crucial for developers in this competitive market and those striving to enter it. With generic alternatives available in all <abbr title=\"Parkinson's disease\">PD<\/abbr> drug classes, it will be critical for new brands to demonstrate clear clinical differentiation to gain uptake.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What comorbidities are most common in <abbr title=\"Parkinson's disease\">PD<\/abbr> patients, and which are most difficult to manage? Which clinical attributes define early, intermediate, and advanced <abbr title=\"Parkinson's disease\">PD<\/abbr>?<\/li>\n<li>What is the patient share for key brands and how do neurologists expect their prescribing to change in the coming year? What are the key drivers and constrainers of their use?<\/li>\n<li>What percentage of Parkinson\u2019s patients develop motor fluctuations or levodopa-induced dyskinesias? What strategies do neurologists use to manage these issues?<\/li>\n<li>What percentage of <abbr title=\"Parkinson's disease\">PD<\/abbr> patients receive treatment for nonmotor symptoms (e.g., orthostatic hypotension, psychosis, dementia)?<\/li>\n<li>How are neurologists using biomarker testing (e.g., alphasynuclein, <abbr title=\"leucine-rich repeat kinase 2\">LRRK2<\/abbr>, <abbr title=\"glucocerebrosidase\">GBA<\/abbr>, <abbr title=\"dopamine transporter\">DAT<\/abbr>)?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul>\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Lundbeck, Supernus<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Crexont, Vyalev, Onapgo, Duopa, Gocovri, Inbrija,\u00a0Neupro, Nourianz, Nuplazid, Ongentys, Rytary, Xadago, all generic mainstays<\/p>\n<p><strong>Primary research: <\/strong>Survey of 100 U.S. neurologists<\/p>\n","protected":false},"template":"","class_list":["post-296405","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-therapy-areas-parkinsons-disease","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296405\/revisions"}],"predecessor-version":[{"id":575181,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296405\/revisions\/575181"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}